Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals has announced updates on its clinical trials for IMM2510/AXN-2510, a PD-L1 and VEGF bispecific antibody, in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) in China. The Phase 2 trial is expected to complete enrollment by the third quarter of 2025, with initial safety and efficacy results anticipated in the second half of 2025. The company plans to initiate a Phase 3 trial in mid-2026, subject to regulatory discussions. The announcement highlights the potential of IMM2510/AXN-2510 to improve treatment outcomes in NSCLC, positioning ImmuneOnco as a competitive player in the oncology field.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company specializes in the development of bispecific antibodies, such as IMM2510/AXN-2510, which target PD-L1 and VEGF for the treatment of multiple solid tumor cancers.
Average Trading Volume: 5,315,076
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.85B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.